Autolus Therapeutics (NASDAQ:AUTL) Reaches New 52-Week Low – Time to Sell?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $2.29 and last traded at $2.29, with a volume of 2277337 shares. The stock had previously closed at $2.49.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AUTL. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics presently has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Trading Up 2.2 %

The firm has a market capitalization of $609.36 million, a price-to-earnings ratio of -1.89 and a beta of 1.98. The company has a 50-day moving average of $3.45 and a 200-day moving average of $3.80.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the company posted ($0.26) EPS. On average, research analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors have recently made changes to their positions in the stock. Exchange Traded Concepts LLC lifted its holdings in shares of Autolus Therapeutics by 9.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock worth $152,000 after purchasing an additional 3,740 shares during the last quarter. Wealth Effects LLC lifted its stake in Autolus Therapeutics by 19.5% in the second quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock valued at $171,000 after buying an additional 8,000 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after acquiring an additional 9,000 shares during the period. State Street Corp grew its position in shares of Autolus Therapeutics by 1.7% during the third quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after acquiring an additional 10,401 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the 2nd quarter worth about $43,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.